You Are Not Buying Stem Cells.
You are buying a chain of custody, a manufacturing process, a delivery method, a risk profile, a follow-up philosophy, and a story. Understanding that distinction is the beginning of due diligence — not the end of it.
The stem cell marketplace operates on a fundamental mismatch. Patients arrive with real pain, real dysfunction, and real desperation. They encounter an industry structured to monetize hope rather than verify outcomes. "Stem cells" now covers everything from rigorously manufactured allogeneic MSCs produced in GMP-certified facilities — like Ryoncil, FDA-approved December 2024 for pediatric steroid-refractory GVHD — to unlabeled biologics of unknown origin administered in countries with no meaningful patient recourse.
The problem is not that stem cell therapy is universally fraudulent. Some of it is legitimate. Some is in active clinical investigation. The problem is that the legitimate and the fraudulent often present identically to a patient without a framework for telling them apart. Same language. Same pricing. Same testimonials. Same white coats.
A 2025 peer-reviewed analysis found that many physician training programs for stem cell interventions are linked to unproven clinics and use sensationalized marketing language emphasizing profits. CME designation does not make a training credible.
What the transaction actually contains
When a provider quotes you a price for stem cell therapy, that number bundles at minimum eight distinct decisions — none disclosed separately, and most you are not being invited to evaluate independently.
- Chain of custody from donor to delivery — including donor screening, processing, testing, storage, and shipping controls.
- Manufacturing process — which may or may not be GMP-compliant, determining viability, contamination risk, and FDA classification under Section 351 versus 361.
- Route of administration — IV, intra-articular, intrathecal — each with different risk profiles, indication logic, and evidence bases. Florida's SB 1768 (July 2025) created a new regulatory gray zone for orthopedic and pain indications.
- Risk profile — known adverse events, adverse event response protocols, hospital transfer agreements.
- Follow-up philosophy — which may be nothing at all once payment clears.
- Clinical evidence base — peer-reviewed and indication-specific, or a plausible mechanism narrative never tested in a controlled setting.
- Legal framework — what you can do if harmed, which may be effectively zero in countries with limited malpractice recourse.
- A marketing claim — the part the provider has rehearsed, and the part least likely to represent the complete picture.
Why this framework exists
The ISSCR's 2025 guidelines are explicit: patients should not be rushed to make decisions, and providers should not financially incentivize consent. If a provider cannot name the manufacturer of the product they propose to administer, they have told you something important — whether or not they know it.
This framework does not protect you from stem cell therapy. It protects you from making an uninformed decision about it — in either direction.